Alyssa Bouska,Weiwei Zhang,Sunandini Sharma,Harald Holte,Ab Rauf Shah,Waseem Gul Lone,Luca Vincenzo Cappelli,Danilo Fiore,Qiang Gong,Tayla Heavican-Foral,Jeffrey Cannatella,Catalina Amador,Aiza Arif,Lynette Smith,Soon Thye Lim,Choon Kiat Ong,Andrew L. Feldman,Ming-Qing Du,Laurence de Leval,Timothy C. Greiner,Kai Fu,Gunhild Trøen,Daniel Vodak,Sigve Nakken,Jan Delabie,David M. Weinstock,Stefano A. Pileri,Antonella Laginestra,Kyeongjin Kim,Utpal Pajvani,Julie M. Vose,Dennis D Weisenburger,Sandeep Dave,Giorgio Inghirami,Wing C. Chan,Javeed Iqbal

Abstract:Follicular helper T-cell lymphoma of the angioimmunoblastic type (AITL) is associated with dismal prognosis. We performed functional genomic approaches including whole-exome sequencing (WES; n=119), transcriptomic (n=78) and methylation (n=40) analysis. We identified recurrent mutations in known epigenetic drivers ( TET2, DNMT3A, IDH2 R172), and also identified novel ones (TET3, KMT2D). Somatic mutation of all three epigenetic drivers ( TET2, IDH2, and DNMT3A) was associated with poor prognosis (p<.001). Mutations in genes regulating T-cell receptor (TCR) signaling ( CD28 VAV1, FYN, PLCG1) or activation ( RHOA G17V), and regulators of the PI3K pathway (PIK(3)C members, PTEN,PHLPP-1/-2) were also found. Genome-wide DNA-methylation analysis integrated with mRNA expression profiling also revealed epigenetic alterations in genes regulating TCR-RHOA/B/C or PI3K-signaling. TET2 loss was noted in 85% AITLs and was significantly associated with RHOA G17V, CD28 and IDH2 R172mutations. AITLs lacking RHOA G17V tended to have mutations regulating the JAK-STAT pathway ( JAK2, JAK3, STAT1, STAT3, SOCS1). RNA-seq analysis identified fusion transcripts in genes regulating TCR activation (8%), revealed a restricted TCR repertoire in the majority of cases (a=87%, b=72%), and showed the presence of Epstein-Barr virus transcriptome (73%). GEP demonstrated association of B-cells in the tumor-milieu with better prognosis (p=.006), while dendritic cells were associated with worse prognosis (p=.001), which was further validated by immunohistochemistry using CD20, CD68, and CD163 antibodies. RNA-seq and corresponding WES analysis of 12 AITL patient-derived-xenografts (PDX) showed that bi-allelic TET2 mutations, DNMT3A mutations or sub-clonal mutations ( PLCG1 PHLPP2) werepropagated in sequential passages. Gene signatures related to T FH (follicular helper) and T CM (central memory) were also well-maintained in secondary passages in PDX models. Gene signatures of late PDX passages (3 rd-5 th) were enriched with genes related to proliferation and metabolic reprogramming, and in an independent cohort of AITLs, high expression of T3/T5 related signatures was associated with worse outcome (p=0.02/p=0.009). Low mRNA expression of PHLPP2 predicted poor prognosis (p=.03) and engineered PHLPP2 loss showed enhanced PI(3)K activation and FOXO1 inactivation in CD4+ T-cells in-vitro. Thus, we defined the genomic landscape for AITL, which is largely characterized by epigenetic alterations, TCR signaling and PI3K/AKT dysregulation, which may be amenable for therapeutic targeting.

A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors

Loss-of-function Mutations in TNFAIP3 Leading to A20 Haploinsufficiency Cause an Early-Onset Autoinflammatory Disease

A novel missense mutation in TNFAIP3 causes haploinsufficiency of A20

A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology

Genetic Mutations Associated With TNFAIP3 (A20) Haploinsufficiency and Their Impact on Inflammatory Diseases

Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

The Complexity of Being A20: From Biological Functions to Genetic Associations

Expanding the Spectrum of A20 Haploinsufficiency in Two Chinese Families: Cases Report

A20 Inactivation in Ocular Adnexal MALT Lymphoma

Novel Loss-of-function Mutations in TNFAIP3 Gene in Patients with Lupus Nephritis.

A20 intrinsically influences human effector T‐cell survival and function by regulating both NF‐κB and JNK signaling

Activation of the NF-κB Pathway and Heterozygous Deletion of TNFAIP3 (A20) Confer Superior Survival in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

A20 Haploinsufficiency Caused by Loss‐of‐function TNFAIP3 Mutation Likely Leads to Progression of Antiphospholipid Syndrome to Marginal Zone Lymphomas Following Coronavirus Disease 2019 Vaccination: A Case Study

Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma

Novel Heterogeneous Mutation of TNFAIP3 in a Chinese Patient with Behçet-Like Phenotype and Persistent EBV Viremia

Gain-of-function IKZF1 variants in humans cause immune dysregulation associated with abnormal T/B cell late differentiation

Loss-of-phosphorylation of IKZF1 results in gain-of-function associated with immune dysregulation

A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell|[ndash]|mediated suppression

TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expression

TNFAIP3 Deletion Status in Classical Hodgkin Lymphoma and Its Relation to Epstein-Barr Virus

A20 is an Antigen Presentation Attenuator, and Its Inhibition Overcomes Regulatory T Cell–mediated Suppression